Stem Cell Delivery Approach Shows Promise for Stroke Recovery
A review led by University of Miami researchers examines how delivering stem cells directly into brain-supplying arteries could support recovery after ischemic stroke and identifies the evidence still needed before the approach becomes part of standard care.
Key Takeaways
- Researchers are studying whether delivering stem cells directly into arteries supplying the injured brain could support recovery after ischemic stroke.
- Intra-arterial delivery may allow more therapeutic cells to reach stroke-affected tissue than intravenous administration.
- Preclinical and early clinical studies have supported the safety and feasibility of stem cell administration, but a definitive improvement in patient function has not been established.
- Future research must identify the appropriate cell type, dose, treatment timing and patients most likely to benefit.
Researchers from the University of Miami Miller School of Medicine and collaborating institutions have published a comprehensive review examining the rapidly evolving field of intra-arterial stem cell therapy for ischemic stroke. The review highlights stem cell therapy’s potential to improve recovery for patients who continue to face disability despite major advances in stroke treatment.
Published in the American Heart Association journal, Stroke: Vascular and Interventional Neurology, the review examines decades of preclinical and clinical research and outlines a roadmap for translating regenerative therapies from the laboratory to the bedside.
Ischemic stroke, in which blood supply to a part of the brain is cut off by a clot blockage, remains one of the leading causes of death and long-term disability worldwide. While clot-busting medications and mechanical thrombectomy have transformed care for acute ischemic stroke, many patients are left with significant neurological deficits despite successful restoration of blood flow.
The authors argue that stem cell therapies delivered directly into the brain’s circulation via catheter angiographic techniques may complement existing treatments. The stem cells promote brain repair, reduce inflammation and enhance recovery.
“Mechanical thrombectomy has revolutionized stroke treatment, but half of the patients still do not regain full independence,” said Dileep Yavagal, M.D., professor of clinical neurology and neurological surgery at the Miller School, director of the neurological stem cell platform at the Interdisciplinary Stem Cell Institute and senior author of the review. “Stem cell therapy represents a promising strategy to help the brain recover after injury and may become an important next step in improving outcomes for stroke patients.”
How Does Intra-Arterial Stem Cell Delivery Work?
Stem cells can be delivered through several different routes and the optimal route in stroke treatment is not yet established. Dr. Yavagal’s review focuses on intra-arterial delivery, an approach during which stem cells are infused directly into arteries supplying the injured region of the brain. Unlike intravenous administration, intra-arterial delivery allows a greater concentration of therapeutic cells to reach stroke-affected tissue. Surgical approaches, by contrast, are more invasive.
Researchers note that intra-arterial delivery is particularly attractive because it can potentially be performed during mechanical thrombectomy. Preclinical studies, including from Dr. Yavagal’s laboratory at the Interdisciplinary Stem Cell Institute, demonstrate that stem cells may reduce inflammation, promote formation of new blood vessels, support neural repair and improve neurological outcomes following stroke. Multiple early-stage clinical trials have also established the feasibility and safety of stem cell administration across several delivery routes.
Why This Research Matters
Many patients continue to experience neurological disability after an ischemic stroke, even when treatment successfully restores blood flow.
Researchers are studying whether stem cells delivered directly into arteries supplying the injured brain could complement existing treatment and support recovery.
Safety and feasibility findings are encouraging, but additional research must determine the best cells, dose, timing and patients before the approach can become part of standard care.
What Does the Evidence Show So Far?
The review analyzes more than two decades of clinical development and notes that more than 40 randomized clinical trials have investigated stem cell therapies for stroke via many different routes of delivery. While safety has been consistently demonstrated, evidence for definitive functional benefit remains under investigation. Several ongoing studies are working to determine optimal cell type, dosing, timing and patient selection strategies.
“The safety of IA stem cell therapy has been established by several preclinical and clinical studies and will continue to remain a critical endpoint for all future studies,” said Roshni Thakkar, Ph.D., co-first author and research assistant professor in the Department of Neurology at the Miller School. “The next challenge that the field is taking on is to identify the right cells, the right dose, the right patients and the right time to intervene in order to maximize stroke recovery.”
The authors emphasize that future studies should integrate advanced imaging, biological markers and immune profiling to better understand how stem cells interact with the post-stroke brain and to identify patients most likely to benefit.
“Regenerative medicine has the potential to fundamentally reshape stroke treatment,” said Nadia McMillan, M.D., Ph.D., co-first author, senior neuro-endovascular fellow and instructor. “The goal is not only to save brain tissue during a stroke but to help patients regain function and quality of life afterward.”
Which Questions Must Researchers Answer Next?
According to the review, emerging therapies may eventually include bioengineered stem cells, extracellular vesicles and exosomes and combination approaches that pair thrombectomy with regenerative treatments. Continued advances could ultimately transform stroke care from a model focused primarily on restoring blood flow to one that also actively promotes brain repair and recovery.
The authors conclude that while significant challenges remain, ongoing clinical trials and rapid advances in regenerative neuroscience provide reason for optimism that stem cell-based therapies may one day become an important adjunct to standard stroke treatment and achieve positive outcomes for the vast majority of stroke patients.
More from the Miller School of Medicine
The Florida Stroke Registry has received a record $2 million state appropriation to strengthen stroke prevention efforts across Florida.
Researchers from the University of Miami Comprehensive Center for Brain Health shared 16 studies at AAIC 2026, highlighting advances in dementia treatment, blood-based biomarkers and early cognitive screening.
Ralph L. Sacco Research Day at the University of Miami spotlights resident and fellow neurology research and emerging clinician‑scientists.
Dr. Dileep Yavagal earns a Lifetime Achievement Award at AAN 2026 for advancing mechanical thrombectomy and equitable stroke care worldwide.
Tags: Department of Neurological Surgery, Department of Neurology, Dr. Dileep Yavagal, neurology, stem cell therapies, stem cells, stroke, stroke outcomes, thrombectomy